Xeris Pharmaceuticals Stock Forecast, Price & News

Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions

Is Xeris Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xeris Pharmaceuticals stock.
View analyst ratings for Xeris Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Xeris Pharmaceuticals?

Wall Street analysts have given Xeris Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Xeris Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Xeris Pharmaceuticals' next earnings date?

Xeris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Xeris Pharmaceuticals.

How were Xeris Pharmaceuticals' earnings last quarter?

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) announced its quarterly earnings results on Thursday, August, 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.11. The firm earned $8.84 million during the quarter, compared to analyst estimates of $9.95 million. Xeris Pharmaceuticals had a negative net margin of 251.01% and a negative trailing twelve-month return on equity of 298.23%.
View Xeris Pharmaceuticals' earnings history.

How has Xeris Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Xeris Pharmaceuticals' stock was trading at $2.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XERS shares have decreased by 16.7% and is now trading at $1.85.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for XERS?

1 brokers have issued 1 year target prices for Xeris Pharmaceuticals' shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Xeris Pharmaceuticals' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 386.5% from the stock's current price.
View analysts' price targets for Xeris Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Xeris Pharmaceuticals' key executives?

Xeris Pharmaceuticals' management team includes the following people:

• Paul R. Edick, Chairman & Chief Executive Officer
• John Patrick Shannon, President & Chief Operating Officer
• Steven Pieper, Chief Financial & Accounting Officer
• Steven Prestrelski, Chief Scientific Officer
• Ken Johnson, SVP-Clinical Development & Regulatory Affairs

Who are some of Xeris Pharmaceuticals' key competitors?

Some companies that are related to Xeris Pharmaceuticals include Geron (GERN), Mirum Pharmaceuticals (MIRM), Vaccitech (VACC), Chinook Therapeutics (KDNY), Bolt Biotherapeutics (BOLT), Verastem (VSTM), Foghorn Therapeutics (FHTX), Flexion Therapeutics (FLXN), Aldeyra Therapeutics (ALDX), Chimerix (CMRX), Greenwich LifeSciences (GLSI), Viking Therapeutics (VKTX), Epizyme (EPZM), AC Immune (ACIU) and Enochian Biosciences (ENOB).
View all of XERS's competitors.

What other stocks do shareholders of Xeris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and OrganiGram (OGI).

When did Xeris Pharmaceuticals IPO?

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Xeris Pharmaceuticals' stock symbol?

Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."

Who are Xeris Pharmaceuticals' major shareholders?

Xeris Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Deltec Asset Management LLC (0.69%), GPS Wealth Strategies Group LLC (0.09%) and Searle & CO. (0.03%). Company insiders that own Xeris Pharmaceuticals stock include John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski.
View institutional ownership trends for Xeris Pharmaceuticals.

Which major investors are buying Xeris Pharmaceuticals stock?

XERS stock was purchased by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC, Searle & CO., and GPS Wealth Strategies Group LLC. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include John Patrick Shannon Jr, and Paul R Edick.
View insider buying and selling activity for Xeris Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Xeris Pharmaceuticals?

Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xeris Pharmaceuticals' stock price today?

One share of XERS stock can currently be purchased for approximately $1.85.

How much money does Xeris Pharmaceuticals make?

Xeris Pharmaceuticals has a market capitalization of $123.02 million and generates $20.16 million in revenue each year. The company earns $-91.14 million in net income (profit) each year or ($2.14) on an earnings per share basis.

How many employees does Xeris Pharmaceuticals have?

Xeris Pharmaceuticals employs 180 workers across the globe.

What is Xeris Pharmaceuticals' official website?

The official website for Xeris Pharmaceuticals is www.xerispharma.com.

Where are Xeris Pharmaceuticals' headquarters?

Xeris Pharmaceuticals is headquartered at 180 N. LaSalle Street Suite 1810, Chicago IL, 60601.

How can I contact Xeris Pharmaceuticals?

Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at (844) 445-5704 or via email at [email protected].